

MayView Community Health Center Inc
270 Grant Ave
Palo Alto, CA, 943061911

Sharp, Andrew
212 Thompson Sq.
Mountain View, CA, 94043
Person #: 34737
Sex: M
DOB: 12/14/1958

Ordering: Gupta MD, Aarti

Performing #: QuestDiag

Location: MCHC PA (Palo Alto)

Tests Ordered : TSH (NG004259), CBC with Diff (NG005009), Hep B Surface Ab (NG006395), HIV Ab (NG083850), LIPID PANEL (NG303756), CMP (NG322000), HEPATITIS PANEL (NG322744)

TSH (Collection Date: 08/22/2017 10:07, Status: Final)

| Component | Result | Units | Flag | Range | Comment |
|-----------|--------|-------|------|-----------|---------|
| TSH | 5.10 | mIU/L | H | 0.40-4.50 | |

no symptoms at present

HIV 1/2 ANTIGEN/ANTIBODY, FOURTH GENERATION W/RFL (Collection Date: 08/22/2017 10:07, Status: Final)

| Component | Result | Units | Flag | Range | Comment |
|--------------------|--------------|-------|------|--------------|---|
| HIV AG/AB, 4TH GEN | NON-REACTIVE | | | NON-REACTIVE | HIV-1 antigen and HIV-1/HIV-2 antibodies were not detected. There is no laboratory evidence of HIV infection. |

PLEASE NOTE: This information has been disclosed to you from records whose confidentiality may be protected by state law. If your state requires such protection, then the state law prohibits you from making any further disclosure of the information without the specific written consent of the person to whom it pertains, or as otherwise permitted by law. A general authorization for the release of medical or other information is NOT sufficient for this purpose.

For additional information please refer to <http://education.questdiagnostics.com/faq/FAQ106> (This link is being provided for informational/educational purposes only.)

The performance of this assay has not been clinically validated in patients less than 2 years old.

HEPATITIS B SURFACE ANTIBODY QL (Collection Date: 08/22/2017 10:07, Status: Final)

| Component | Result | Units | Flag | Range | Comment |
|---------------------------------|--------------|-------|------|--------------|---------|
| HEPATITIS B SURFACE ANTIBODY QL | NON-REACTIVE | | | NON-REACTIVE | |

Recommend Hep B vaccine 3 doses over 6 months

CBC (INCLUDES DIFF/PLT) (Collection Date: 08/22/2017 10:07, Status: Final)

| Component | Result | Units | Flag | Range | Comment |
|----------------------|--------|----------|------|-----------|---------|
| ABSOLUTE BASOPHILS | 42 | cells/uL | | 0-200 | |
| ABSOLUTE EOSINOPHILS | 238 | cells/uL | | 15-500 | |
| ABSOLUTE LYMPHOCYTES | 2338 | cells/uL | | 850-3900 | |
| ABSOLUTE MONOCYTES | 700 | cells/uL | | 200-950 | |
| ABSOLUTE NEUTROPHILS | 3682 | cells/uL | | 1500-7800 | |
| BASOPHILS | 0.6 | % | | | |
| EOSINOPHILS | 3.4 | % | | | |
| HEMATOCRIT | 42.1 | % | | 38.5-50.0 | |

*0, 1 month - 6 months
1st 2nd 3rd dose*

Patient: Sharp, Andrew , DOB: 12/14/1958

| | | | |
|------------------------|------|-------------|------------|
| HEMOGLOBIN | 14.5 | g/dL | 13.2-17.1 |
| LYMPHOCYTES | 33.4 | % | |
| MCH | 31.5 | pg | 27.0-33.0 |
| MCHC | 34.4 | g/dL | 32.0-36.0 |
| MCV | 91.3 | fL | 80.0-100.0 |
| MONOCYTES | 10.0 | % | |
| MPV | 10.0 | fL | 7.5-12.5 |
| NEUTROPHILS | 52.6 | % | |
| PLATELET COUNT | 260 | Thousand/uL | 140-400 |
| RDW | 12.6 | % | 11.0-15.0 |
| RED BLOOD CELL COUNT | 4.61 | Million/uL | 4.20-5.80 |
| WHITE BLOOD CELL COUNT | 7.0 | Thousand/uL | 3.8-10.8 |

COMPREHENSIVE METABOLIC PANEL (Collection Date: 08/22/2017 10:07, Status: Final)

| Component | Result | Units | Flag | Range | Comment |
|-------------------------|----------------|---------------|------|-----------|--|
| ALBUMIN | 4.3 | g/dL | | 3.6-5.1 | |
| ALBUMIN/GLOBULIN RATIO | 1.6 | (calc) | | 1.0-2.5 | |
| ALKALINE PHOSPHATASE | 43 | U/L | | 40-115 | |
| ALT | 49 | U/L | H | 9-46 | ? medication fatty liver disease /obesity alcoholism |
| AST | 33 | U/L | | 10-35 | |
| BILIRUBIN, TOTAL | 0.6 | mg/dL | | 0.2-1.2 | |
| BUN/CREATININE RATIO | NOT APPLICABLE | (calc) | | 6-22 | |
| CALCIUM | 9.4 | mg/dL | | 8.6-10.3 | |
| CARBON DIOXIDE CHLORIDE | 23 | mmol/L | | 20-31 | |
| | 105 | mmol/L | | 98-110 | |
| CREATININE | 0.94 | mg/dL | | 0.70-1.33 | For patients >49 years of age, the reference limit for Creatinine is approximately 13% higher for people identified as African-American. |
| eGFR AFRICAN AMERICAN | 103 | mL/min/1.73m2 | > OR | = 60 | |
| eGFR NON-AFR. AMERICAN | 89 | mL/min/1.73m2 | > OR | = 60 | |
| GLOBULIN | 2.7 | g/dL (calc) | | 1.9-3.7 | |
| GLUCOSE | 97 | mg/dL | | 65-99 | Fasting reference interval |
| POTASSIUM | 4.1 | mmol/L | | 3.5-5.3 | |
| PROTEIN, TOTAL | 7.0 | g/dL | | 6.1-8.1 | |
| SODIUM | 141 | mmol/L | | 135-146 | |
| UREA NITROGEN (BUN) | 11 | mg/dL | | 7-25 | |

? medication
fatty liver disease /obesity
alcoholism
exercise- 30min
fast walking daily

LIPID PANEL (Collection Date: 08/22/2017 10:07, Status: Final)

| Component | Result | Units | Flag | Range | Comment |
|-----------|--------|-------|------|-------|---------|
|-----------|--------|-------|------|-------|---------|

Patient: Sharp, Andrew , DOB: 12/14/1958

CHOL/HDL-C RATIO 4.3 (calc) <5.0
 CHOLESTEROL, TOTAL 210 mg/dL H <200
 HDL CHOLESTEROL 49 mg/dL >40
 LDL-CHOLESTEROL 135 mg/dL H (calc)

*good chol
Bad chol*

*higher the better - exercise daily & weight control
low cholesterol / low fat diet*

Reference range: <100

Desirable range <100 mg/dL for patients with CHD or diabetes and <70 mg/dL for diabetic patients with known heart disease.

The Martin-Hopkins calculation is a validated novel method that provides better accuracy than the Friedewald equation in the estimation of LDL-C, particularly when TG levels are 150-400 mg/dL and LDL-C levels are lower than 70 mg/dL. Reference: Martin SS et al. Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels From the Standard Lipid Profile. JAMA. 2013;310(19): 2061-2068.

NON HDL CHOLESTEROL 161 mg/dL H <130 (calc)

For additional information, please refer to <http://education.QuestDiagnostics.com/faq/FAQ164> (This link is being provided for informational/educational purposes only.)

For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.

TRIGLYCERIDES 139 mg/dL <150

HEPATITIS PANEL, ACUTE W/REFLEX TO CONFIRMATION (Collection Date: 08/22/2017 10:07, Status: Final)

| Component | Result | Units | Flag | Range | Comment |
|---------------------------------|--------------|-------|------|--------------|---------|
| HEPATITIS A IGM | NON-REACTIVE | | | NON-REACTIVE | |
| HEPATITIS B CORE ANTIBODY (IGM) | NON-REACTIVE | | | NON-REACTIVE | |
| HEPATITIS B SURFACE ANTIGEN | NON-REACTIVE | | | NON-REACTIVE | |
| HEPATITIS C ANTIBODY | NON-REACTIVE | | | NON-REACTIVE | |
| SIGNAL TO CUT-OFF | 0.01 | | | <1.00 | |